在患有非神经性出血的患者中,用于逆转XA因子抑制剂的四因子原素复合度的固定与基于体重的剂量
Tyson Stokes1, Christopher Johnson1, Tyler Fish1
1Department of Pharmacy, St. Luke's Health System, ID, USA.
Journal of pharmacy practice
|February 8, 2025
概括
固定剂量 (2000 单位) 四因子前列红素复合物缩物 (4F-PCC) 在非神经性出血中显示出与基于体重的剂量相似的静血疗效,用于非神经性出血中的XA因子抑制剂逆转. 这一发现支持使用固定的剂量来改善患者管理.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 有证据表明,固定的剂量四因子前素复合缩物 (4F-PCC) 是安全和有效的XA因子抑制剂 (FXaI) 逆转.
- 基于体重的剂量是4F-PCC管理的常见替代方案.
研究的目的:
- 为了比较固定剂量 (2000 单位) 与基于体重 (50 单位/公斤) 的4F-PCC在患有非神经性出血的患者中的静血疗效.
- 评估FXaI逆转的不同4F-PCC剂量策略的安全性和有效性.
主要方法:
- 18岁以上接受4F-PCC治疗FXaI逆转的患者的多中心,回顾性图表审查.
- 纳入标准:非神经性出血,一剂4F-PCC,以及可用的抗FXa水平.
- 血液静止疗效定义为没有出血进展,Hgb下降,并保持抗FXa水平.
主要成果:
- 分析了59名患者 (29名基于体重,30名固定剂量).
- 静血疗效率相似:固定剂量93.3%,基于体重的93.1% (P=1).
结论:
- 固定剂量4F-PCC是非神经性出血中FXaI逆转的安全有效选择.
- 这项研究支持使用固定的剂量,可能简化治疗方案.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Dosage Regimen: Fixed Dose
1.8K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.8K
Extrinsic and Intrinsic Pathways of Hemostasis
4.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose
3.8K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.8K
Clot Retraction and Fibrinolysis
3.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.5K


